New hope for rare blood cancer: drug combo trial launches

NCT ID NCT04061421

Recruiting now Disease control Sponsor: Michael Savona Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 20, 2026 · Updated 8 times

Summary

This study tests new combinations of oral drugs for people with MDS/MPN, a rare group of blood cancers. The goal is to find safe doses and see if the treatments shrink or control the cancer. About 94 adults who have not had treatment or whose cancer returned will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Moffitt Cancer Center
SUSPENDED

Tampa, Florida, 33612, United States
Oregon Health Sciences University
RECRUITING

Portland, Oregon, 97239, United States

Contact Email: •••••@•••••
University of Rochester Wilmot Cancer Institute
RECRUITING

Rochester, New York, 14609, United States

Contact Email: •••••@•••••
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MDS/MPN